Risperidone vs Cariprazine — Cost, Coverage & Plan Comparison

Pick the drugs you want to compare.

Up to 4 drugsCross-class or same-class

Start with the molecules your plan spends the most on. Most useful comparisons live within the same therapeutic class — switching across classes requires deeper clinical review.

Drug 1

Drug 2

Drug 3 (optional)

Drug 4 (optional)

Side by side, line by line.

Federal data onlyNo PBM pricing assumed

Compare across

11 dimensions

Atypical Antipsychotic

Risperidone

Brand: PERSERIS

First FDA approval: 1993-12-29

Atypical Antipsychotic

Cariprazine

Brand: Vraylar

First FDA approval: 2015-09-17

Lowest NADACAcquisition cost floor across all NDCs

$0.036Per unit

$50.91Per unit

Average NADACAcross all dosage forms and strengths

$460.75Up to $9451.01

$50.95Up to $50.96

Generic manufacturersActive ANDA holders — FDA Orange Book

25123 total ANDAs filed

00 total ANDAs filed

Annualized Part D spendCY2024 — CMS Part D Spending Dashboard

$283.1MFull year

$1.75BFull year

Part D claims (CY24)Total fills, all strengths

5.7M904K beneficiaries

1.2M216K beneficiaries

Avg cost per claimCalculated: total spend ÷ total claims

$50Per claim, all NDCs

$1,489Per claim, all NDCs

Part D plans surveyed2026 plan year — CMS Formulary file

329Across CMS plan year

Prior-authorization frictionPlan-NDC pairs requiring PA

611Substantial friction

308Substantial friction

Step therapy appliedPlan-NDC pairs requiring step therapy

414Limited friction

256Limited friction

FDA shortage statusLive cross-reference vs FDA Drug Shortage Database

NoneClear

Generic availableFDA Orange Book

Yes25 manufacturers

NoBrand-only